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One-Year Outcomes of Prenatal Exposure to MDMA
and Other Recreational Drugs
WHAT’S KNOWN ON THIS SUBJECT: 3,4-Methylenedioxymetham-
phetamine (MDMA, ecstasy) is a widely used recreational drug
affecting the serotonergic system. Preclinical studies indicate
learning/memory problems with fetal exposure. Human infant
prenatal exposure was related to alterations in gender ratio
and poorer motor development at 4 months.
WHAT THIS STUDY ADDS: This is the ﬁrst study documenting that
heavier prenatal 3,4-methylenedioxymethamphetamine exposure
predicts poorer infant mental and motor development at 12
months with signiﬁcant, persistent neurotoxic effects. Language
and emotional regulation were unaffected.
abstract
OBJECTIVE: A widely used illicit recreational drug among young adults,
3,4-methylenedioxymethamphetamine (MDMA) or ecstasy, is an indirect
monoaminergic agonist/reuptake inhibitor affecting the serotonin system.
Preclinical studies found prenatal exposure related to long-term learning
and memory impairments. There are no studies of sequelae of prenatal
MDMA exposure in humans, despite potential harmful effects to the fetus.
METHODS: A total of 96 women in the United Kingdom (28 MDMA users; 68
non-MDMA) were interviewed about recreational drug use during
pregnancy. Their infants were seen at 12 months using standardized
assessments of cognitive, language, and motor development (Preschool
Language Scale, Bayley Mental and Motor Development and Behavior
Rating Scales [Mental Development Index, Psychomotor Development
Index, Behavioral Rating Scale]). Mothers completed the Child Domain
Scale of the Parenting Stress Index, The Home Observation of the
Environment Scale (in interview), the Brief Symptom Inventory, and the
Drug Abuse Screening Test. Women were primarily middle class with
some university education, in stable partner relationships, and polydrug
users. MDMA and other drug effects were assessed through multiple
regression analyses controlling for confounding variables, and analysis
of covariance comparing heavier versus lighter and nonexposed groups.
RESULTS: Amount of prenatal MDMA exposure predicted poorer infant
mental and motor development at 12 months in a dose-dependent
manner. Heavily exposed infants were delayed in motor development.
Lighter-exposed infants were comparable to nonexposed infants. There
were no effects on language, emotional regulation, or parenting stress.
CONCLUSIONS: Findings document persistent neurotoxic effects of
heavier prenatal MDMA exposure on motor development through
the ﬁrst year of life. Pediatrics 2012;130:407–413
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A popular, illicit drug used recreationally
worldwide, particularly among young
adults inEurope,Australia,andtheUnited
Statesaspartof thedanceclubculture, is
3,4-methylenedioxymethamphetamine
(MDMA) or ecstasy.1,2 A derivative of
amphetamine, MDMAhas both stimulant
and hallucinogenic effects in adults3 and
primarily affects serotonergic (5-HT)
neurons, but also activates noradrener-
gic and dopaminergic sites.3 Adults ex-
perience a range of acute and long-term
effects, including immediate feelings of
euphoria, openness, and energy, al-
though chronic use is associated with
depression and possible cognitive im-
pairments in memory and executive
function.4 Serotonergic neurotoxicity has
been conﬁrmed in a number of human
neuroimaging studies.5 Because of ma-
ternal physiologic effects of hyperther-
mia and appetite suppression and direct
effects on the fetal serotonin system,
MDMA exposure may be harmful to the
developing fetus.6
Preclinical studies indicate that prenatal
MDMA exposure may induce behavioral
alterations of long-term memory and
learning impairments and increased
locomotor activity.7–9 First-trimester ex-
posure has been related to reduced
birth weight, increased locomotor ac-
tivity, and learning deﬁcits,9 as well as
long-term behavioral alternations of re-
duced anxiety, heightened response to
novelty, and hyperattentiveness during
spatial learning.10 Recent studies in-
dicate structural and functional changes
in the noradrenergic system related to
attention.11 Small case series studies of
human pregnancy outcomes in the
United Kingdom and the Netherlands
found a higher incidence of congenital
malformations in MDMA-exposed preg-
nancies.12,13
In the ﬁrst, to our knowledge, human
studyofMDMA-exposed infants,we found
prenatal exposure associated with al-
terations in gender ratio at birth and
poorer motor quality and milestone
delaysneonatallyandat4monthsofage
in a middle-class, UK sample of recre-
ational drug users.14 The current arti-
cle presents the results of follow-up of
that cohort at 12 months of age.
METHODS
All mothers and infants were pro-
spectively recruited through the Case
Western Reserve University and Univer-
sity of East London (UEL) Drugs and In-
fancy Study of recreational drug use in
pregnant women.15,16 Participants were
recruited throughmidwives, response to
leaﬂets distributed at prenatal clinics, or
advertisements in pregnancymagazines.
Study description requested participa-
tion of pregnant women who had used
recreational drugs during pregnancy,
listing ecstasy, tobacco, cannabis, alco-
hol, and cocaine as examples. Exclu-
sionary factors included maternal/child
HIV-positive status, maternal moderate/
severe mental retardation or severe
psychiatric or medical illness; or, for the
child, other major medical illnesses. All
participants were ensured of conﬁden-
tiality and gave informedwritten consent
approved by university (Case Western
Reserve University and UEL) and National
Health Service (UK) ethics committees.
Of 126 respondents, 5 did notmeet study
criteria and 25 did not come to the ﬁrst
visit (4 had miscarriages; 1 withdrew
because of depression, 2 to partner’s
objection, 3 with no reason; 1 moved out
of range, and 14 could not be contacted).
Of 96 subjects enrolled and seen for in-
fant testing during the course of the
study, 79 infants (82%) were seen at 12
months.
Measures of MDMA Exposure and
Covariates
Women were interviewed about their
substance use by trained research
assistants in their homes or at the UEL
laboratory, or, for a small number, by
telephone. Women were interviewed
over the course of pregnancy on 3
separate occasions, but if necessary,
a combined set of interviews was given
on 1 occasion for enrollment late in pre-
gnancy.15 Sixty-two women completed
the interview during pregnancy, and 24
postnatally.
The interview was an adaptation of the
Maternal Post-Partum Interviewused in
previous studies of substance expo-
sure17 and asked women to describe
their intake of those commonly used in
UK cohorts.18 Information taken included
total lifetime drug use, use during the
year before conception, and use in the
month before and over the trimesters of
pregnancy for each drug. Values were
computed for tobacco/cigarettes (num-
ber), alcohol (numberof units),marijuana
joints/cigarettes (number), MDMA tab-
lets (number), heroin cigarettes or in-
jections (number), ketamine (grams),
crack (number of rocks) or cocaine
(number of lines), benzodiazepine and
LSD tablets (number), and hallucino-
genic mushrooms (number). Frequency
of use for each drug was recorded on
a scale ranging from 0 (none) to 7 (daily
use). An average dose perweek for each
drug was calculated by multiplying the
frequency by the amount taken per oc-
casion. Information was also obtained
for typical and highest consumption.
Women were considered users if they
admitted to MDMA use during preg-
nancy or in themonth before pregnancy.
Women were administered the Drug
Abuse Screening Test,19 a 20-item self-
report scale validated against the Di-
agnostic and Statistical Manual of
Mental Disorders, Third Edition, that
yields a quantitative index of life
problems related to drug use. A score
of 16 (of 20) indicates a severe level of
problems.
The Brief Symptom Inventory (BSI),20
a widely used reliable, 53-item self-
report questionnaire was given to
describe experience of a range of psy-
chiatric symptoms at each visit. The
BSI yields 9 subscales and a summary
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score, the General Severity Index, that
measures overall psychological distress.
BSI data from the 1-month and 12-month
visits were used.
Maternal age, marital status, ethnicity,
educational level, andhousehold income
were obtained. Two subtests of the
Wechsler Abbreviated Scale of Intelli-
gence,21 a standardized IQ test (Block
Design and Similarities), were admin-
istered. Each subtest yields a t score
with mean of 50 and SD of 8.
At the 12-month visit, mothers were
administered the Child Domain Scale of
the Parenting Stress Index22 to assess
parental stress about child charac-
teristics. The Child Domain has 6 char-
acteristics (adaptability, acceptability,
distractibility-hyperactivity, mood, de-
mandingness, and reinforces parent).
Normative data were derived from 534
families with children from 1 month to
19 years.
The Home Observation of the Environ-
ment23 was also administered in inter-
view format to measure quality of the
caregiving environment.
Infants were given the Bayley Scales of
Infant Development,24 widely used
standardized, valid, reliable assessments
of development. The Mental Scale yields
a Mental Development Index (MDI) re-
ﬂectingmemory, language, and problem-
solving abilities. The Psychomotor Index
(PDI) measures gross and ﬁne motor
control and coordination. Normative data
yield a mean of 100 and SD of 15. The
Behavioral Rating Scale assesses quality
of infant performance across several
domains based on assessor observa-
tions, including orientation, motor qual-
ity, and emotional regulation.
Infants were also given the Preschool
Language Scale,25 a standardized, nor-
mative language assessment composed
of Auditory Comprehension and Expres-
sive Communication subscales with re-
ceptive and expressive language tasks
for ages birth to 4 years 11 months.
Assessorsweremaster’s level psychology
assistants or the equivalent masked to
infant drug exposure.
Statistical Analyses
The effects of MDMA were assessed
through a series of linear regression
analysesusingtheaveragedoseofMDMA
per week consumed during pregnancy
and the month previous averaged over
the time period as the independent
variable. Interaction effects of gender,
demographic, andotherdrug exposures
were also tested if signiﬁcant main ef-
fects were found.
To determine covariates, group compar-
isons were conducted between mothers
who used MDMA during pregnancy (n =
28) and those who had not (n = 68) with
exposure deﬁned dichotomously (coded
as 1 for exposed), and, based on our
4-month ﬁndings and because drugs
may have effects only at certain thresh-
olds, as heavier, lighter, or nonexposed
(2, 1, 0) based on a median split of the
exposed group. Differences between ex-
posed and nonexposed groups were ex-
amined for maternal use of other drugs
and psychological distress using x2 or
Fisher’s exact test for dichotomous varia-
bles and t-test or Wilcoxon–Mann-Whitney
test. Log transformations were used to
correct skewness. Univariate analyses
were conducted on maternal factors and
prenatal drug exposures. Spearman cor-
relation analyses were used to assess the
relationships of amount and frequency of
drug exposure and other covariates to
infant outcomes. Variables included infant
age at testing and all maternal demo-
graphic and infant birth variables.
Covariates different by group and re-
lated to the outcome at P , .2 were
evaluated in regression models step-
wise and retained if, on entry, they
were signiﬁcant at P , .10 or caused
substantial change (. 10%) in the
MDMA coefﬁcient.
Planned analyses of covariance were
conducted to illustrate the functioning
of the drug-exposed groups, and to
compare heavier to lighter and non-
exposed infants, based on previous
4-month outcomes. With a = 0.05 and
power of 0.80, the sample size could
detect moderate effect sizes with up to
4 predictors in regression models.
RESULTS
Table 1 reports characteristics of
women who used MDMA versus women
who did not use MDMA while pregnant.
The maternal sample at enrollment
was primarily white, married or with
a partner, with some university educa-
tion, middle socioeconomic status, and
in the average range of intellectual
ability. MDMA-using women differed
from nonusing women only in having
fewer children. Overall prenatal drug
use and the negative sequelae of drug
use differed between groups (Tables 1
and 2). Women who used MDMA during
pregnancy had higher Drug Abuse
Screening Test scores, indicating greater
severity of sequelae from drug use, al-
though both groups scored very low.
All births were singleton and birth
parameter outcomes did not differ by
groupexcept thatMDMA-exposedinfants
weremore likely to bemale. One child in
the MDMA group was diagnosed with
Townes-BrocksSyndrome,araregenetic
autosomal dominant multiple malfor-
mation of the gene SALL1.26 All out-
comes with signiﬁcant ﬁndings were
rerun excluding this child and results
did not differ. Thus, the presented ﬁnd-
ings include all in the MDMA-exposed
group.
Compared with mothers who came to
the 12-month assessment, mothers who
did not come were younger, less edu-
cated,hada lowerscoreon theWechsler
Abbreviated Scale of Intelligence Simi-
laritiessubtest,andusedmorecigarettes
during pregnancy. No other difference
was found. Table 2 describes the char-
acteristics of mothers and infants seen
at 12 months compared by heavier,
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lighter, and nonexposed status, indicat-
ing similar differences as seen in the
dichotomous comparisons.
Table 3 describes the average and me-
dian drug use for heavier, lighter, and
no-use groups across all substances
reported. MDMA users used more to-
bacco, marijuana, cocaine, amphet-
amines, LSD, and mushrooms than
nonusers. Non-MDMA users were more
likely to decrease their use of other
drugs during pregnancy than MDMA
users (see Moore et al15 and Singer
et al14 for details). Over the pregnancy,
most MDMA users discontinued use,
with only 1 woman reporting use in the
third trimester.
Before pregnancy, the mean number of
tablets ingested perweekwas 3.2 (SD =
5.2, Range = 0.1–26.3) for those who
used MDMA during pregnancy. The
mean total amount of MDMA used
during pregnancy and the month pre-
vious was 25 tablets (SD = 43.7, Range =
0.45–180). Heavier users averaged
3.3 (64) tablets in the month before
pregnancy compared with 0.12 6 0.2
tablets for lighter users (Wilcoxon test
P, .007); 1.66 2 vs 0.126 1 tablets in
the ﬁrst trimester (P, .12), and 0.156
0.6 vs 0.02 6 0.1 in the second tri-
mester (P . .20).
Child Outcomes at 12 Months
Higher amounts of MDMA exposure
predicted poorer mental and motor
outcomes and assessor ratings of
poorer motor quality at 12 months,
controlling for covariates (see Tables 4,
5, 6, and 7). Group outcomes based on
heavier, lighter, and no exposure in-
dicated that infants with heavier expo-
sure had a 5-point deﬁcit in MDI,
compared with lighter and nonexposed
MDI children. Two children in the more
heavily exposed group were in the at-
risk range (,85), compared with no
children in the other groups. Greater
deﬁcits related to heavier MDMA ex-
posure were found in motor outcomes,
with most of the more heavily exposed
children classiﬁed as at-risk (PDI ,
85), and one-third demonstrating sig-
niﬁcant developmental delay (PDI ,
70), compared with less than a third at-
risk and,10% in the delayed range in
the lighter and nonexposed groups.
There was also a nonsigniﬁcant trend
for MDMA exposure to predict less
orientation and engagement (b = –1.9,
t = –1.7, P , .09).
MDMA exposure was unrelated to
language or emotional regulation out-
comes. Lighter MDMA-exposed infants
were equivalent to nonexposed in-
fants on all outcomes. There were no
differences in maternal report of par-
enting stress related to child charac-
teristics.
Several family characteristics and drug
exposures had effects on outcomes in
additiontoMDMA.TheHomeObservation
of the Environmentwasrelated tohigher
MDI (b = 0.65, t = 2.4, P , .02), and
better emotional regulation (b = 3.01,
t = 3.01, P, .004), orientation (b = 0.24,
t = 2.2, P, .03), and language scores (all
with P, .05). Higher maternal General
Severity Index predicted greater child
domain stress (b = 0.60, t = 1.9, P ,
.057). Boys had lower MDI (b = –4.0, t =
2.0, P , .05), and lower emotional reg-
ulation scores (b = –15.3, t = –2.1, P,
.036). Higher alcohol exposure pre-
dicted better orientation (b = 6.86 3.0,
t = 2.5, P , .02) and expressive lan-
guage (b = 2.96 1.0, t = 3.1, P, .003),
whereas higher crack-cocaine exposure
predicted lower expressive language
scores (b = –5.3 6 –2.5, t = –2.1,
P , .04).
DISCUSSION
At 12 months of age, amount of MDMA
exposure had negative effects on infant
cognitive and motor outcomes and
examiners’ ratings of motor quality,
suggesting signiﬁcant developmental
TABLE 1 Maternal and Child Characteristics
MDMA (n = 28) Non-MDMA (n = 68) x2/t P
Maternal characteristics
White, n (%) 23 (85) 57 (84) 0.3 .87
Registered disabled, n (%) 0 (0) 5 (8) 0.19 .32
Married/with partner, n (%) 22 (79) 57 (84) 0.38 .54
Family income, n (%) 1.59 .81
,10K British Pounds 4 (14) 13 (19)
10–40K British Pounds 17 (61) 40 (59)
.40K British Pounds 7 (25) 15 (22)
Maternal age at birth, mean (SD) 28.4 (6.2) 30.3 (6.4) 1.33 .19
Maternal education, mean (SD) 15.3 (2.7) 14.9 (2.9) 20.57 .57
WASI Block Design, mean (SD) 57.0 (8.1) 56.0 (9.5) 20.43 .67
WASI Similarities, mean (SD) 51.4 (8.5) 49.4 (8.9) 20.88 .38
Parity, mean (SD) 1.21 (0.42) 1.88 (1.11) 4.27 .0001
General Severity Index, mean (SD) 0.71 (0.81) 0.51 (0.47) 20.61 .54
DAST score, mean (SD) 7.7 (4.1) 4.6 (4.4) 23.09 .03
Home Observation of the Environment
score, mean (SD)
40.2 (3.3) 39.6 (3.53) 20.69 .49
Child characteristics
White, n (%) 20 (71) 51 (75) 0.13 .72
Male, n (%) 20 (71) 31 (46) 5.32 .02
Special Baby Care Unit, n (%) 3 (11) 8 (12) 0.27 1.00
Gestation, wk, mean (SD) 40.0 (1.6) 39.5 (1.5) 21.41 .16
Preterm (,37 wk), n (%) 1 (3.6) 1 (1.5) 0.43 .50
Birth weight, g,a mean (SD) 3537 (500) 3344 (511) 2.10 .15
Birth length, cm,b mean (SD) 52.0 (2.6) 51.4 (2.7) 20.56 .58
Head circumference, cm,c mean (SD) 34.8 (1.8) 34.3 (1.9) 20.97 .34
DAST, Drug Abuse Screening Test; WASI, Wechsler Abbreviated Scale of Intelligence.
a Adjusted for infant gender.
b Based on reduced sample of 31 and 10.
c Based on reduced sample of 39 and 16.
410 SINGER et al
 by guest on February 13, 2014pediatrics.aappublications.orgDownloaded from 
risk for themore heavilyMDMA-exposed
infant. The most pronounced effects
were on motor outcomes. Motor delays
were consistent with previous ﬁndings
at 4 months in the same cohort of
slower and more delayed movements
and 1-month trends of more lethargic
behaviors in the MDMA group. At 12
months, delays were noted in stand-
ing and walking progressions.
MDMA primarily affects the serotonin
(5-HT)neurotransmitter thatplaysakey
role in brain morphogenesis and is one
of theﬁrst neurotransmitters to appear
in the central nervous system.27 MDMA
treatment in animals correspondent to
human prenatal exposure has been
shown to disrupt the serotonergic sys-
tem and induces the release of the stress
hormone cortisol.7 Many aspects of mo-
tor control have a serotonergic input,
and serotoninmay bemore implicated in
gross skeletal rather than ﬁne or dis-
cretemusclemovements.28 At 12months,
the Bayley Mental Scale items also have
a strong motor component, as language
is not yet well developed, and tasks at 12
months require ﬁnemotor skills, such as
placement of pegs in a pegboard. Thus,
subtle MDI deﬁcits seen may be attrib-
utable to ﬁne motor impairments.
Preclinical studies of animals exposed
neonatally to MDMA resulted in alter-
ations in dose-dependent learning that
persisted to adulthood,29 as well as
spatial and working memory deﬁcits,30
reduced interest in novelty,28 and
hypoactivity.28 There are no other
comparative human studies of MDMA
exposure on infant mental or motor
development.
TABLE 2 Sample Characteristics at 1-Year Follow-up by Heavier, Lighter, and Non-MDMA Exposure
(n = 79)
MDMA Status x2/F P
Heavier (n = 10) Lighter (n = 12) None (n = 57)
Maternal characteristics
White, n (%) 9 (90) 10 (83) 40 (70) 2.33 .42
Registered disabled, n (%) 0 0 4 (7) 1.61 .99
Married/with partner, n (%) 9 (90) 9 (75) 48 (84) 0.96 .62
Family income, n (%) 9.88 .32
,10K British Pounds 0 4 (33) 9 (16)
10–40K British Pounds 6 (60) 6 (50) 34 (60)
.40K British Pounds 4 (40) 2 (17) 14 (25)
Maternal age at birth, mean (SD) 28.5 (6.9) 29.5 (5.3) 31.0 (6.4) 0.83 .44
Maternal education, mean (SD) 15.4 (2.7) 15.5 (3.2) 15.3 (2.8) 0.03 .97
WASI Block Design, mean (SD) 55.0 (9.34) 60.0 (5.32) 57.0 (8.94) 0.72 .49
WASI Similarities, mean (SD) 48.2 (6.8) 56.3 (7.8) 50.4 (8.1) 2.43 .10
Parity, mean (SD) 1.10 (0.32) 1.25 (0.45) 1.86 (1.19) 3.44 .04
General Severity Index (at 12 mo),
mean (SD)
0.50 (0.43) 0.61 (0.71) 0.50 (0.41) 0.10 .91
General Severity Index (birth),
mean (SD)
0.63 (0.78) 0.78 (0.87) 0.51 (0.47) 0.54 .58
DAST score, mean (SD) 6.9 (4.3) 7.8 (3.5) 4.7 (4.6) 3.03 .054
Home Observation of the Environment
score, mean (SD)
40.5 (3.66) 39.9 (3.09) 39.6 (3.53) 0.31 .73
Child characteristics
White, n (%) 8 (80) 9 (75) 42 (74) 0.18 .99
Male, n (%) 6 (60) 10 (83) 26 (46) 5.88 .051
Special Baby Care Unit, n (%) 1 (10) 1 (8.3) 8 (14.3) 0.39 .99
Gestation, wk, mean (SD) 40.0 (1.33) 40.1 (2.11) 39.3 (1.5) 1.72 .19
Preterm (,37 wk), n (%) 0 1 (8.3) 1 (1.8) 2.04 .48
Birth weight, g, mean (SD) 3392 (506) 3513 (553) 3267 (502) 1.25 .29
Birth length, cm, mean (SD) 54.0 (1.41) 50.6 (2.88) 51.1 (2.680) 1.23 .31
Head circumference, cm, mean (SD) 35.3 (1.23) 35.7 (1.83) 34.2 (2.01) 2.04 .14
DAST, Drug Abuse Screening Test; WASI, Wechsler Abbreviated Scale of Intelligence.
TABLE 3 Average Maternal Drug Use During Pregnancy by Heavier, Lighter, and Non-MDMA Exposure
Drug, per wk MDMA Status x2a P
Heavier (n = 13) Lighter (n = 15) None (n = 68)
Mean (SD) Median (Range) Mean (SD) Median (Range) Mean (SD) Median (Range)
Cigarettes 50.2 (39.9) 45.0 (0–118) 23.8 (36.8) 9.6 (0–123) 32.5 (49.1) 13.19 (0–280) 4.63 .10
Alcohol, units 12.5 (16.0) 4.9 (0.06–51) 6.06 (4.52) 5.25 (0–14.7) 6.6 (12.9) 2.3 (0–84) 4.25 .12
Marijuana, joints 9.9 (24.2) 0.25 (0–87.5) 9.51 (14.79) 3.40 (0.01–3.4) 6.3 (15.0) 0.06 (0–88) 6.48 .04
MDMA, tablets 1.3 (1.4) 0.75 (0.17–4.5) 0.07 (0.04) 0.06 (0.01–0.14) — — — —
Cocaine, doses 0.15 (0.28) 0.05 (0–1.0) 0.24 (0.64) 0.005 (0–2.4) 0.02 (0.1) 0 (0–0.8) 28.6 .0001b
Crack, rocks 0.04 (0.11) 0 (0–0.37) 0.01 (0.04) 0 (0–0.17) 1.0 (5.0) 0 (0–38) 0.43 .81
Amphetamine, doses 0.03 (0.10) 0 (0–0.33) 0.05 (0.14) 0 (0–0.52) 0.0003 (0.001) 0 (0–0.01) 4.8 .09
Mushrooms, doses 0.02 (0.07) 0 (0–0.25) 0.003 (0.007) 0 (0–0.02) 0 (0) 0 (0–0) 8.2 .02
Tranquilizers, doses 0.23 (0.83) 0 (0–3) 0.003 (0.01) 0 (0–0.04 0.4 (1.9) 0 (0–11) 0.27 .87
Opiates, doses 0.25 (0.86) 0 (0–3.13) 0.02 (0.08) 0 (0–0.31) 0.2 (1.2) 0 (0–8) 0.70 .71
LSD, doses 0 0 0.03 (0.07) 0 (0–0.25) 0 (0) 0 (0–0) 16.5 .0003
Ketamine 0.13 (0.49) 0 (0–1.75) 0.001 (0.005) 0 (0–0.02) 0 0 5.0 .08
a Kruskal-Wallis test.
b Post hoc test Lighter group differ from None (P , .02).
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Strengths of this study include the
measurement of potential confounders
of maternal education, quality of the
caregiving environment, and other drug
exposures. Women were recruited vol-
untarily during pregnancy without threat
of legal action, enhancing reliability
of drug information obtained through
self-report. Although self-report of
drug use may be unreliable, particu-
larly when women may have concerns
about fetal health and social stigma,
minimization of drug use would serve
to mask differences between groups;
however, functional outcomes in this
study differed by amount of MDMA ex-
posure, suggesting validity to maternal
self-report.
Selection bias may be a concern if
participants had concerns for risk
that precipitated their study in-
volvement, although both MDMA and
non-MDMA users could be presumed
to have been similar in that regard.
Because fetal exposure was almost
entirely restricted to the ﬁrst and
second trimesters, results are not
generalizable to longer-term expo-
sure. Womenwith greater concern for
pregnancy and fetal health may have
been more likely to enroll and dis-
continue or decrease drug use than
those who chose not to enroll, and
may not be representative of all users.
The present ﬁndings suggest that
even the offspring of women who
discontinue use are at increased risk
for developmental delays at higher
exposure levels. Although there were
no effects at lighter exposures, sam-
ple size may have been too small to
detect subtle effects at lower expo-
sure levels.
The sample size for MDMA users
was small but did not contain con-
founding factors seen in most drug-
exposure studies, allowing greater
statistical power. Participants were
largely of middle socioeconomic sta-
tus, had average intelligence and
education, were employed, and most
were married or in stable partnered
relationships.
Despite some limitations, the current
study provides the ﬁrst prospective
developmental follow-up of MDMA-
exposed infants. Findings of poorer
cognitive and motor development at 1
year of age with heavier exposure to
MDMA in the ﬁrst 2 trimesters suggest
signiﬁcant risk for later learning
problems. Because infant outcomes in
TABLE 4 Effects of Amount of MDMA Exposure Over Pregnancy and Month Previous on Bayley
Mental Development Index at 12 Months
Predictor Parameter Estimate (b) SE t P b
MDMA 28.19 3.17 22.58 ,.012 20.28
Gender 24.32 1.84 22.35 ,.021 20.25
Home Observation of the Environment 0.59 0.27 2.23 ,.029 0.24
F(3, 76) = 5.28, P , .002, R2 = 0.18.
TABLE 5 Effects of Amount of MDMA Exposure Over Pregnancy and Month Previous on Bayley
Psychomotor Development Index at 12 Months
Predictor Parameter Estimate (b) SE t P b
MDMA 215.75 (6.2) 6.19 22.54 ,.013 20.28
Marijuana 2.55 (1.3) 1.33 1.92 ,.058 0.21
F(2, 77) = 5.67, P , .005, R2 = 0.13.
TABLE 6 Effects of MDMA Exposure Over Pregnancy and Month Previous on Bayley Behavioral
Rating Scale Motor Quality at 12 Months
Predictor Parameter Estimate (b) SE t P b
MDMA 217.40 7.45 22.33 ,.022 20.26
Home Observation of the Environment 0.91 0.63 1.45 .15 0.16
F(2, 76) = 3.89, P , .025, R2 = 0.10.
TABLE 7 Twelve-Month (Adjusted) Outcomes by Heavier Versus Lighter and Nonexposed MDMA
Status, Mean (SD)
MDMA Status
Heavier (n = 10) Lighter (n = 12) None (n = 57) F/ x2 P
Age, mo 12.6 (0.65) 13.2 (2.1) 12.8 (0.56) 0.60 .44
MDIa 98.5 (11.4) 103.4 (6.3) 103.4 (8.5) 3.50 ,.07
% , 85, n (%) 2 (20) 0 0 — —
% , 70, n (%) 0 0 0 — —
PDIb 76.0 (11.8) 99.8 (12.3) 92.0 (16.4) 10.65 ,.002
% , 85, n (%) 8 (80%) 2 (17%) 17 (30%) 10.69 ,.002
% , 70, n (%) 3 (30%) 0 4 (7%) 6.34 ,.04
Behavioral Rating Percentile
Emotional Regulationa 66.4 (32) 57.8 (34) 61.8 (32) 0.15 ,.71
Orientationc 54.9 (33) 70.6 (26) 65.5 (25) 2.7 ,.11
Motor Qualityd 71.3 (32) 88.8 (15) 87.6 (17) 12.4 ,.001
Preschool Language Scale
Auditory Comprehensiond 93.1 (6.9) 87.5 (5.1) 92.7 (8.9) 0.16 ,.69
Expressive Communicatione 97.2 (10.4) 99.5 (7.8) 95.8 (9.9) 0.10 ,.75
Total Languagee 94.9 (8.5) 93.0 (5.9) 94.4 (8.4) 0.00 ,.98
Parenting Stress Child Domainf 92.2 (29) 89.6 (11) 90.9 (18) 0.07 ,.79
a Adjusted for gender, Home Observation of the Environment.
b Adjusted for marijuana.
c Adjusted for alcohol, marijuana, Home Observation of the Environment, gender.
d Adjusted for Home Observation of the Environment.
e Adjusted for alcohol, crack-cocaine, Home Observation of the Environment.
f Adjusted for General Severity Index.
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the range found in this cohort are not
necessarily predictive of long-term
outcomes, follow-up to older ages is
important to determine whether these
early cognitive and motor differences
persist or resolve.
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